ProCE Banner Activity

Phase II Study of Poziotinib, an Investigational TKI, in Heavily Pretreated EGFR or HER2 Exon 20–Mutated NSCLC

Slideset Download
Conference Coverage
ORRs of 50% to 55% observed across patient cohorts treated with poziotinib.

Released: October 02, 2018

Expiration: October 01, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants

AbbVie

AstraZeneca

Genentech TEXT Only

Takeda Oncology